South America mulls centralized price negotiations for hep C drugs
This article was originally published in Scrip
Executive Summary
Members of UNASUR, the Union of South American Nations, could combine their bargaining power to drive down the price of the new hepatitis C drugs, such as Gilead's Sovaldi. If successful, such a move could set an uncomfortable precedent for drug companies selling expensive new drugs in the region.
You may also be interested in...
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.
New HTA Evidence Guidelines In EU Could Spell Trouble For Advanced Therapy Companies
New guidelines that cast doubt over use of single-arm and non-randomized studies are “discouraging” for rare disease patients and the advanced therapy sector, says ARM, the Alliance for Regenerative Medicines.
Germany Courts Clinical Trials With Regulator Reshuffle & New Federal Ethics Committee
Plans to rejig two regulators’ roles and streamline the ethics committee system have drawn some criticism.